Get the Stockscreener App
19.97
1.47%
0.29
Upstream Bio Inc stock is traded at $19.97, with a volume of 556.12K.
It is up +1.47% in the last 24 hours and up +28.84% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$19.68
Open:
$19.81
24h Volume:
556.12K
Relative Volume:
1.14
Market Cap:
$1.08B
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-15.54
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
+16.58%
1M Performance:
+28.84%
6M Performance:
+135.77%
1Y Performance:
+0.00%
1-Day Range:
$19.09
$20.42
1-Week Range:
$16.66
$21.03
52-Week Range:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
19.97 | 1.06B | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio Inc. stock momentum explained2025 Price Momentum & Expert Approved Trade Ideas - Newser
Is Upstream Bio Inc. meeting your algorithmic filter criteriaWeekly Trade Report & Safe Capital Growth Trade Ideas - Newser
Visual trend scoring systems applied to Upstream Bio Inc.M&A Rumor & Daily Stock Trend Reports - Newser
Historical volatility pattern of Upstream Bio Inc. visualizedEarnings Miss & Community Supported Trade Ideas - Newser
Using fundamentals and technicals on Upstream Bio Inc.Trade Analysis Summary & Weekly Stock Breakout Alerts - Newser
Statistical indicators supporting Upstream Bio Inc.’s strength2025 Analyst Calls & Technical Confirmation Trade Alerts - Newser
Using portfolio simulators with Upstream Bio Inc. included2025 Buyback Activity & Expert Verified Stock Movement Alerts - Newser
How to interpret RSI for Upstream Bio Inc. stock2025 Market Sentiment & Safe Entry Trade Reports - Newser
Upstream Bio’s Phase 2 VIBRANT Trial Results and Strategic Implications for Long-Term Growth - AInvest
Is Upstream Bio Inc. stock poised for growthMarket Performance Summary & Consistent Profit Focused Trading Strategies - Newser
Is now a turning point for Upstream Bio Inc.Portfolio Gains Report & Accurate Buy Signal Notifications - Newser
Will Upstream Bio Inc. benefit from geopolitical trendsJuly 2025 Catalysts & Short-Term Swing Trade Alerts - خودرو بانک
Can Upstream Bio Inc. outperform in the next rally2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - خودرو بانک
Long term hold vs stop loss in Upstream Bio Inc.Price Action & Free Technical Confirmation Trade Alerts - Newser
Is Upstream Bio Inc. stock a top performer YTDWeekly Trend Report & Free Safe Capital Growth Stock Tips - خودرو بانک
Transcript : Upstream Bio, Inc.Special Call - MarketScreener
Is Upstream Bio Inc. forming a bottoming baseJuly 2025 Market Mood & Real-Time Stock Movement Alerts - Newser
Trend analysis for Upstream Bio Inc. this weekPortfolio Growth Summary & Real-Time Chart Pattern Alerts - Newser
Using economic indicators to assess Upstream Bio Inc. potentialJuly 2025 Retail & AI Enhanced Trade Execution Alerts - Newser
Technical signs of recovery in Upstream Bio Inc.2025 Breakouts & Breakdowns & AI Powered Market Entry Strategies - Newser
Exit strategy if you’re trapped in Upstream Bio Inc.Trade Entry Summary & Verified Short-Term Plans - Newser
Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug - MSN
What MACD and RSI say about Upstream Bio Inc.2025 Major Catalysts & AI Powered Buy/Sell Recommendations - Newser
How to build a dashboard for Upstream Bio Inc. stock2025 Top Gainers & Fast Gain Stock Tips - Newser
Real time breakdown of Upstream Bio Inc. stock performanceMarket Performance Recap & High Accuracy Swing Entry Alerts - Newser
Analyzing Upstream Bio Inc. with risk reward ratio chartsWeekly Profit Analysis & High Conviction Buy Zone Alerts - Newser
Does Upstream Bio Inc. offer margin of safetyMarket Risk Report & Capital Efficiency Focused Strategies - خودرو بانک
Will Upstream Bio Inc. outperform during market ralliesMarket Sentiment Report & Daily Entry Point Trade Alerts - خودرو بانک
Upstream Bio Inc. stock outlook for YEAR2025 Momentum Check & High Win Rate Trade Alerts - Newser
Is Upstream Bio Inc. a strong candidate for buy and holdQuarterly Trade Review & Reliable Breakout Stock Forecasts - خودرو بانک
Upstream Bio Announces Positive Phase 2 Trial Results - The Globe and Mail
Developing predictive dashboards with Upstream Bio Inc. dataRate Cut & Technical Pattern Recognition Alerts - Newser
Upstream Bio shares rise 1.18% premarket after reporting positive top-line results from the Phase 2 VIBrant trial of Verekitug for the treatment of chronic rhinosinusitis with nasal polyps. - AInvest
Upstream Bio, Inc. $UPB Shares Sold by Charles Schwab Investment Management Inc. - Defense World
Signal strength of Upstream Bio Inc. stock in tech scannersRecession Risk & Low Drawdown Investment Ideas - Newser
Upstream Bio Reports Positive Top-Line Results from the - GlobeNewswire
Upstream Bio Shares Surge 18.27% on Strong Phase 2 Trial Data for Verekitug - AInvest
Technical Heatmap Flags Upstream Bio Inc. for WatchCPI Data & Safe Entry Zone Tips - beatles.ru
Verekitug heads to late-stage trials after Phase II success - Yahoo Finance
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial FindsUpstream Bio (NASDAQ:UPB) - Benzinga
Upstream Bio’s Phase 2 win could set it up as a potential Dupixent, Tezspire competitor - Endpoints News
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Upstream Bio Inc Stock (UPB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):